The Value of Gadobenate Dimeglumine-enhanced Biliary Imaging from the Hepatobiliary Phase for Predicting Post-hepatectomy Liver Failure in HCC Patients

Overview

Journal Eur Radiol

Specialty Radiology

Date 2022 May 31

PMID 35639146

Authors

Dongxiao Meng

Changhu Liang

Yuanwen Zheng

Ximing Wang

Keke Liu

Zhengyu Lin

Qiang Zhu

Xinya Zhao

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine the value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure (PHLF) in patients with hepatocellular carcinoma (HCC).

Methods: Patients with HCC who underwent gadobenate dimeglumine-enhanced hepatobiliary magnetic resonance imaging prior to hepatectomy were collected in two centers. The relative enhancement ratio of the biliary system (REB) and the liver to muscle ratio (LMR) were measured at the hepatobiliary phase. Potential risk factors for PHLF were analyzed by logistic regression. The capacity of the REB and LMR to predict PHLF was analyzed via receiver operating characteristic curve.

Results: Of the 221 patients, post-hepatectomy liver failure occurred in 60 patients (27.1%). The REB was an independent risk factor for PHLF (odds ratio [OR] = 0.127 [0.047-0.348], p < 0.001). Although the LMR tended to be associated with PHLF (p = 0.063), it was not an independent risk factor in the multivariable analysis (OR = 0.624 [0.023-16.709], p = 0.779). Moreover, the area under the receiver operating characteristic curve of the REB and LMR was 0.87 and 0.60. The most appropriate cutoff value for the REB was 2.21. The HCC patients with the REB ≤ 2.21 had a higher incidence of post-hepatectomy liver failure than those with the REB > 2.21 (60.0% versus 8.5%, p < 0.001).

Conclusions: Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase was valuable in predicting post-hepatectomy liver failure in HCC patients.

Key Points: • The relative enhancement ratio of the biliary system (REB) was an independent risk factor for post-hepatectomy liver failure in HCC patients. • HCC patients with the REB ≤ 2.21 had significantly higher incidence of post-hepatectomy liver failure than those with the REB > 2.21 (60.0% versus 8.5%).

Citing Articles

Predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma: nomograms based on deep learning analysis of gadoxetic acid-enhanced MRI.

Jeong B, Heo S, Lee S, Kim S, Shin Y, Kim K Eur Radiol. 2024; .

PMID: 39528755 DOI: 10.1007/s00330-024-11173-w.

Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: A multicenter study.

Wang J, Zheng T, Liao Y, Geng S, Li J, Zhang Z Front Oncol. 2022; 12:986867.

PMID: 36408144 PMC: 9667038. DOI: 10.3389/fonc.2022.986867.

Progress of modern imaging modalities in multiple myeloma.

Terao T, Matsue K Int J Hematol. 2022; 115(6):778-789.

PMID: 35532876 DOI: 10.1007/s12185-022-03360-6.

References

Rahbari N, Garden O, Padbury R, Brooke-Smith M, Crawford M, Adam R . Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011; 149(5):713-24. DOI: 10.1016/j.surg.2010.10.001. View

Prodeau M, Drumez E, Duhamel A, Vibert E, Farges O, Lassailly G . An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy. J Hepatol. 2019; 71(5):920-929. DOI: 10.1016/j.jhep.2019.06.003. View

Wang Y, Xiang B, Ma L, Zhong J, Ye J, Wang K . Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. Ann Surg. 2020; 274(6):e1209-e1217. DOI: 10.1097/SLA.0000000000003803. View

Franco D, Capussotti L, Smadja C, Bouzari H, Meakins J, Kemeny F . Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology. 1990; 98(3):733-8. View

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

Jelic S, Sotiropoulos G . Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v59-64. DOI: 10.1093/annonc/mdq166. View

Kokudo T, Hasegawa K, Shirata C, Tanimoto M, Ishizawa T, Kaneko J . Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer. 2019; 8(6):447-456. PMC: 6883438. DOI: 10.1159/000501368. View

Wang Y, Zhao X, Ma L, Ye J, Wu F, Tang J . Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol. 2018; 118(3):440-445. DOI: 10.1002/jso.25184. View

Wang Y, Zhong J, Su Z, Huang J, Lu S, Xiang B . Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016; 103(6):725-734. DOI: 10.1002/bjs.10095. View

10.

Dong J, Yang S, Zeng J, Cai S, Ji W, Duan W . Precision in liver surgery. Semin Liver Dis. 2013; 33(3):189-203. DOI: 10.1055/s-0033-1351781. View

11.

Bonatti M, Valletta R, Zamboni G, Lombardo F, Senoner M, Simioni M . Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin. Eur Radiol. 2019; 29(6):2830-2836. DOI: 10.1007/s00330-018-5932-y. View

12.

Zhao X, Huang M, Zhu Q, Wang T, Liu Q . The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magn Reson Imaging. 2015; 33(6):768-73. DOI: 10.1016/j.mri.2015.03.006. View

13.

Schneider G, Altmeyer K, Kirchin M, Seidel R, Grazioli L, Morana G . Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol. 2007; 42(2):105-15. DOI: 10.1097/01.rli.0000251539.05400.06. View

14.

Liu C, Sun Y, Yang Y, Feng Y, Xie X, Qi L . Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis. Eur Radiol. 2021; 31(8):5840-5850. DOI: 10.1007/s00330-021-07702-6. View

15.

Zhang Y, Tang W, Xie S, Chen J, Zhang L, Rong D . The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria. Eur Radiol. 2021; 31(10):7715-7724. DOI: 10.1007/s00330-021-07807-y. View

16.

Li X, Chen Z, Xiao E, Shang Q, Ma C . Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis. World J Gastroenterol. 2017; 23(17):3133-3141. PMC: 5423050. DOI: 10.3748/wjg.v23.i17.3133. View

17.

Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y . Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. Radiology. 2019; 294(1):98-107. DOI: 10.1148/radiol.2019190734. View

18.

Wibmer A, Prusa A, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A . Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology. 2013; 269(3):777-86. DOI: 10.1148/radiol.13130210. View

19.

Asenbaum U, Kaczirek K, Ba-Ssalamah A, Ringl H, Schwarz C, Waneck F . Post-hepatectomy liver failure after major hepatic surgery: not only size matters. Eur Radiol. 2018; 28(11):4748-4756. PMC: 6182758. DOI: 10.1007/s00330-018-5487-y. View

20.

Chuang Y, Ou H, Lazo M, Chen C, Chen M, Weng C . Predicting post-hepatectomy liver failure by combined volumetric, functional MR image and laboratory analysis. Liver Int. 2017; 38(5):868-874. DOI: 10.1111/liv.13608. View